Results 281 to 290 of about 65,436 (336)
Some of the next articles are maybe not open access.
Blood Reviews, 1990
Adequate iron chelation in thalassaemia has resulted in a striking improvement in survival, with a reduction of cardiac mortality at age 15 years from 14-3%, and a predicted survival at age 36 years of 85%. Long term desferrioxamine (DF) therapy in thalassaemic children should be started between 2-4 years of age.
C, Hershko, A, Pinson, G, Link
openaire +3 more sources
Adequate iron chelation in thalassaemia has resulted in a striking improvement in survival, with a reduction of cardiac mortality at age 15 years from 14-3%, and a predicted survival at age 36 years of 85%. Long term desferrioxamine (DF) therapy in thalassaemic children should be started between 2-4 years of age.
C, Hershko, A, Pinson, G, Link
openaire +3 more sources
Annual Review of Medicine, 2009
Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8–12 h/day, 5–7 days/week. Oral iron chelators are an important development, offering the potential to improve compliance and patients’ quality of life.
M.D. Cappellini, P. Pattoneri
openaire +2 more sources
Deferoxamine (DFO) was the standard of care for transfusional iron overload for >40 years, requiring subcutaneous infusion for 8–12 h/day, 5–7 days/week. Oral iron chelators are an important development, offering the potential to improve compliance and patients’ quality of life.
M.D. Cappellini, P. Pattoneri
openaire +2 more sources
CRC Critical Reviews in Clinical Laboratory Sciences, 1988
Because of the catalytic action of iron in one-electron redox reactions, it has a key role in the formation of harmful oxygen derivatives and production of peroxidative damage to vital cellular structures. The clinical manifestations of iron overload may be prevented and even reversed by the effective administration of the iron-chelating drug ...
Chaim Hershko +2 more
openaire +2 more sources
Because of the catalytic action of iron in one-electron redox reactions, it has a key role in the formation of harmful oxygen derivatives and production of peroxidative damage to vital cellular structures. The clinical manifestations of iron overload may be prevented and even reversed by the effective administration of the iron-chelating drug ...
Chaim Hershko +2 more
openaire +2 more sources
Journal of the American Medical Association, 1958
Administration of effective doses of iron in the treatment of iron deficiency anemia is complicated by the fact that iron compounds are not innocuous. Toxicity experiments on dogs and rabbits are here summarized; they showed that the concentration of iron attained in the animal's serum determined the severity of the acute symptoms.
M, FRANKLIN +3 more
openaire +2 more sources
Administration of effective doses of iron in the treatment of iron deficiency anemia is complicated by the fact that iron compounds are not innocuous. Toxicity experiments on dogs and rabbits are here summarized; they showed that the concentration of iron attained in the animal's serum determined the severity of the acute symptoms.
M, FRANKLIN +3 more
openaire +2 more sources
2002
Iron overload is a serious clinical condition which can be largely prevented by the use of iron-specific chelating agents. Desferrioxamine-B(1)the most widely used iron chelator in haematology over the past thirty years, has a major disadvantage of being orally inactive’.
Liu, Z D, Liu, D Y, Hider, R C
openaire +3 more sources
Iron overload is a serious clinical condition which can be largely prevented by the use of iron-specific chelating agents. Desferrioxamine-B(1)the most widely used iron chelator in haematology over the past thirty years, has a major disadvantage of being orally inactive’.
Liu, Z D, Liu, D Y, Hider, R C
openaire +3 more sources
1994
The design of an orally active, non-toxic, selective iron chelator has been a goal of many medical chemists over the past twenty years. Naturally occurring siderophores provide excellent models for such molecules, indeed, desferrioxamine has been and still remains an extremely useful iron chelator.
R C, Hider +3 more
openaire +2 more sources
The design of an orally active, non-toxic, selective iron chelator has been a goal of many medical chemists over the past twenty years. Naturally occurring siderophores provide excellent models for such molecules, indeed, desferrioxamine has been and still remains an extremely useful iron chelator.
R C, Hider +3 more
openaire +2 more sources
Current Opinion in Hematology, 1995
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
International Journal for Vitamin and Nutrition Research, 2004
Iron amino acid chelates, such as iron glycinate chelates, have been developed to be used as food fortificants and therapeutic agents in the prevention and treatment of iron deficiency anemia. Ferrous bis-glycine chelate (FeBC), ferric tris-glycine chelate, ferric glycinate, and ferrous bis-glycinate hydrochloride are available commercially.
Eva, Hertrampf, Manuel, Olivares
openaire +2 more sources
Iron amino acid chelates, such as iron glycinate chelates, have been developed to be used as food fortificants and therapeutic agents in the prevention and treatment of iron deficiency anemia. Ferrous bis-glycine chelate (FeBC), ferric tris-glycine chelate, ferric glycinate, and ferrous bis-glycinate hydrochloride are available commercially.
Eva, Hertrampf, Manuel, Olivares
openaire +2 more sources
Blood Reviews, 2002
In patients with transfusion-dependent anemias, iron accumulation is fatal in the absence of chelating therapy. Extended survival, free of most complications of iron overload is observed in patients treated with early, adequate parenteral deferoxamine.
L, Merson, N, Olivier
openaire +2 more sources
In patients with transfusion-dependent anemias, iron accumulation is fatal in the absence of chelating therapy. Extended survival, free of most complications of iron overload is observed in patients treated with early, adequate parenteral deferoxamine.
L, Merson, N, Olivier
openaire +2 more sources
Current Opinion in Hematology, 2014
This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development.Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years.
openaire +2 more sources
This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development.Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years.
openaire +2 more sources